X |
Filing Date |
Trade Date |
Ticker |
Insider Name | Title |
Trade Type |
Price |
Qty |
Owned |
ΔOwn |
Value |
1d |
1w |
1m |
6m |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
2025-03-03 | NVCR | Leonard Frank X | EVP, Pres, Novocure Oncology | S - Sale | $18.54 | -2,527 | 143,673 | -2% | -$46,841 | ||||||
| AM | 2025-02-27 | NVCR | Leonard Frank X | EVP, Pres, Novocure Oncology | S - Sale | $19.70 | -15,036 | 146,200 | -9% | -$296,257 | |||||
| M | 2025-02-27 | NVCR | Leonard Frank X | EVP, Pres, Novocure Oncology | S - Sale | $19.70 | -15,036 | 146,200 | -9% | -$296,257 | |||||
2024-11-01 | NVCR | Leonard Frank X | EVP, Pres, Novocure Oncology | S - Sale | $15.94 | -598 | 161,236 | 0% | -$9,531 | ||||||
| M | 2024-03-01 | NVCR | Leonard Frank X | EVP, Pres, Novocure Oncology | S - Sale | $16.02 | -2,519 | 160,098 | -2% | -$40,358 | |||||
| D | 2024-02-28 | NVCR | Leonard Frank X | EVP, Pres, Novocure Oncology | S - Sale+OE | $16.14 | -2,078 | 162,617 | -1% | -$33,545 |
| A | Amended filing |
| D | Derivative transaction in filing (usually option exercise) |
| E | Error detected in filing |
| M | Multiple transactions in filing; earliest reported transaction date and weighted average transaction price |
| S - Sale | Sale of securities on an exchange or to another person |
| S - Sale+OE | Sale of securities on an exchange or to another person (after option exercise) |
| F - Tax | Payment of exercise price or tax liability using portion of securities received from the company |
| P - Purchase | Purchase of securities on an exchange or from another person |